Abbott Laboratories has been granted a patent for a method, system, and external instrument that allows for efficient communication between an external instrument and an implantable medical device. The method involves initiating a communication link, establishing a connection interval, monitoring connection criteria such as data throughput, and changing the connection interval based on the criteria. The patent also includes a claim for terminating the connection link based on a comparison of the connection criteria to a threshold. GlobalData’s report on Abbott Laboratories gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Abbott Laboratories, NSAID cancer drugs was a key innovation area identified from patents. Abbott Laboratories's grant share as of September 2023 was 55%. Grant share is based on the ratio of number of grants to total number of patents.
Method for managing communication link between external instrument and implantable medical device
A recently granted patent (Publication Number: US11778674B2) describes a method and system for managing communications sessions between an external instrument (EI) and an implantable medical device (IMD). The method involves initiating a communications session between the EI and IMD and collecting connection criteria for the session, including data throughput. The connection criteria are then compared to a threshold, and based on this comparison, the connection link for the session is terminated.
The method can be performed either by the EI or the IMD. If the connection criteria do not meet the threshold, the connection link is terminated, and an advertising notice is transmitted from the IMD to establish a new communications session. The termination of the connection link can be based on a comparison of the data transfer rate associated with the session and the threshold.
The connection criteria can also relate to connection loss or breakdown. The communications session can include multiple segments with different connection intervals (CI). During each segment, the EI and IMD utilize a specific CI to convey different types of data packets. The EI can interrogate the IMD for the first type of data packets during the first segment. The first CI is shorter than the second CI, allowing for a larger number of data packets to be transmitted in a shorter period of time.
The system described in the patent includes an EI with memory and a processor, which initiates the communications session, collects connection criteria, compares them to a threshold, and terminates the connection link. After termination, the system enters a scan state to search for an advertising notice from the IMD for establishing a new communications session. The system can also determine the data transfer rate associated with the session and terminate the connection link based on this rate.
The IMD in the system includes a sensing circuit, memory, processor, and a radio frequency (RF) circuit. The EI and IMD utilize different connection intervals during different segments of the communications session to convey different types of data packets. The system allows for communication with multiple IMDs, initiating separate communications sessions with each IMD using the appropriate connection interval.
Overall, this patent describes a method and system for managing communications sessions between an external instrument and an implantable medical device, allowing for efficient data transfer and termination of connections based on specific criteria.
To know more about GlobalData’s detailed insights on Abbott Laboratories, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.